1. Home
  2. PAHC vs JANX Comparison

PAHC vs JANX Comparison

Compare PAHC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAHC
  • JANX
  • Stock Information
  • Founded
  • PAHC 1946
  • JANX 2017
  • Country
  • PAHC United States
  • JANX United States
  • Employees
  • PAHC N/A
  • JANX N/A
  • Industry
  • PAHC Biotechnology: Pharmaceutical Preparations
  • JANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PAHC Health Care
  • JANX Health Care
  • Exchange
  • PAHC Nasdaq
  • JANX Nasdaq
  • Market Cap
  • PAHC 1.5B
  • JANX 1.4B
  • IPO Year
  • PAHC 2014
  • JANX 2021
  • Fundamental
  • Price
  • PAHC $38.81
  • JANX $27.68
  • Analyst Decision
  • PAHC Hold
  • JANX Strong Buy
  • Analyst Count
  • PAHC 4
  • JANX 11
  • Target Price
  • PAHC $27.50
  • JANX $76.55
  • AVG Volume (30 Days)
  • PAHC 256.6K
  • JANX 898.3K
  • Earning Date
  • PAHC 11-05-2025
  • JANX 11-05-2025
  • Dividend Yield
  • PAHC 1.27%
  • JANX N/A
  • EPS Growth
  • PAHC 1895.04
  • JANX N/A
  • EPS
  • PAHC 1.19
  • JANX N/A
  • Revenue
  • PAHC $1,296,215,000.00
  • JANX $439,000.00
  • Revenue This Year
  • PAHC $14.80
  • JANX N/A
  • Revenue Next Year
  • PAHC $3.16
  • JANX $91.66
  • P/E Ratio
  • PAHC $31.66
  • JANX N/A
  • Revenue Growth
  • PAHC 27.37
  • JANX N/A
  • 52 Week Low
  • PAHC $16.16
  • JANX $21.73
  • 52 Week High
  • PAHC $41.57
  • JANX $71.71
  • Technical
  • Relative Strength Index (RSI)
  • PAHC 57.53
  • JANX 63.94
  • Support Level
  • PAHC $35.81
  • JANX $25.18
  • Resistance Level
  • PAHC $41.36
  • JANX $26.73
  • Average True Range (ATR)
  • PAHC 1.31
  • JANX 1.46
  • MACD
  • PAHC -0.40
  • JANX 0.42
  • Stochastic Oscillator
  • PAHC 50.45
  • JANX 94.06

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: